Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Oct;85(8):1193–1200. doi: 10.1054/bjoc.2001.2057

Cathepsin S in tumours, regional lymph nodes and sera of patients with lung cancer: relation to prognosis

J Kos 1,2, A Sekirnik 1, G Kopitar 1, N Cimerman 2, K Kayser 3, A Stremmer 3, W Fiehn 4, B Werle 3,4
PMCID: PMC2375152  PMID: 11710834

Abstract

Cysteine proteinase cathepsin S (Cat S) is expressed mainly in lymphatic tissues and has been characterised as a key enzyme in major histocompatibility complex class II (MHC-II) mediated antigen presentation. Cat S has been measured in tissue cytosols of lung parenchyma, lung tumours and lymph nodes and in sera of patients with lung tumours and of healthy controls, by specific enzyme-linked immunosorbent assay (ELISA). A difference in Cat S level was found between tumour and adjacent control tissue cytosols of 60 lung cancer patients (median 4.3 vs. 2.8 ng mg−1protein). In lymph nodes obtained from 24 patients of the same group, the level of Cat S was significantly higher than in tumours or lung parenchyma (P< 0.001). Additionally, significantly higher levels were found in non-infiltrated than in infiltrated lymph nodes (median 16.6 vs 7.5 ng mg−1protein). Patients with low levels of Cat S in tumours and lung parenchyma exhibited a significantly higher risk of death than those with high levels of Cat S (P= 0.025 – tumours;P= 0.02 – parenchyma). Immunohistochemical analysis (IHA) of lung parenchyma revealed a staining reaction in alveolar type II cells, macrophages and bronchial epithelial cells. In regional lymph node tissue, strong staining of Cat S was found in lymphocytes and histiocytes. Nevertheless, Cat S was detected also in tumour cells, independently of their origin. Our results provide evidence that Cat S may be involved in malignant progression. Its role, however, differs from that of the related Cats B and L and could be associated with the immune response rather than with remodelling of extracellular matrix. © 2001 Cancer Research Campaign  http://www.bjcancer.com

Keywords: Cathepsin S, lung tumours, ELISA, monoclonal antibody, MHC-II, immunohistochemistry

Full Text

The Full Text of this article is available as a PDF (126.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abel U., Berger J., Wiebelt H. CRITLEVEL: an exploratory procedure for the evaluation of quantitative prognostic factors. Methods Inf Med. 1984 Jul;23(3):154–156. [PubMed] [Google Scholar]
  2. Barna B., Deodhar S. D. The activity of regional nodes in the evolution of immune responses to allogeneic and isogeneic tumors. Cancer Res. 1975 Apr;35(4):920–926. [PubMed] [Google Scholar]
  3. Brömme D., Bonneau P. R., Lachance P., Storer A. C. Engineering the S2 subsite specificity of human cathepsin S to a cathepsin L- and cathepsin B-like specificity. J Biol Chem. 1994 Dec 2;269(48):30238–30242. [PubMed] [Google Scholar]
  4. Brömme D., Steinert A., Friebe S., Fittkau S., Wiederanders B., Kirschke H. The specificity of bovine spleen cathepsin S. A comparison with rat liver cathepsins L and B. Biochem J. 1989 Dec 1;264(2):475–481. doi: 10.1042/bj2640475. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chapman H. A., Riese R. J., Shi G. P. Emerging roles for cysteine proteases in human biology. Annu Rev Physiol. 1997;59:63–88. doi: 10.1146/annurev.physiol.59.1.63. [DOI] [PubMed] [Google Scholar]
  6. Guncar G., Pungercic G., Klemencic I., Turk V., Turk D. Crystal structure of MHC class II-associated p41 Ii fragment bound to cathepsin L reveals the structural basis for differentiation between cathepsins L and S. EMBO J. 1999 Feb 15;18(4):793–803. doi: 10.1093/emboj/18.4.793. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Hsu S. M., Raine L., Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem. 1981 Apr;29(4):577–580. doi: 10.1177/29.4.6166661. [DOI] [PubMed] [Google Scholar]
  8. Kirschke H., Wiederanders B., Brömme D., Rinne A. Cathepsin S from bovine spleen. Purification, distribution, intracellular localization and action on proteins. Biochem J. 1989 Dec 1;264(2):467–473. doi: 10.1042/bj2640467. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Kopitar G., Dolinar M., Strukelj B., Pungercar J., Turk V. Folding and activation of human procathepsin S from inclusion bodies produced in Escherichia coli. Eur J Biochem. 1996 Mar 1;236(2):558–562. doi: 10.1111/j.1432-1033.1996.00558.x. [DOI] [PubMed] [Google Scholar]
  10. Kos J., Lah T. T. Cysteine proteinases and their endogenous inhibitors: target proteins for prognosis, diagnosis and therapy in cancer (review). Oncol Rep. 1998 Nov-Dec;5(6):1349–1361. doi: 10.3892/or.5.6.1349. [DOI] [PubMed] [Google Scholar]
  11. Kos J., Nielsen H. J., Krasovec M., Christensen I. J., Cimerman N., Stephens R. W., Brünner N. Prognostic values of cathepsin B and carcinoembryonic antigen in sera of patients with colorectal cancer. Clin Cancer Res. 1998 Jun;4(6):1511–1516. [PubMed] [Google Scholar]
  12. Lemere C. A., Munger J. S., Shi G. P., Natkin L., Haass C., Chapman H. A., Selkoe D. J. The lysosomal cysteine protease, cathepsin S, is increased in Alzheimer's disease and Down syndrome brain. An immunocytochemical study. Am J Pathol. 1995 Apr;146(4):848–860. [PMC free article] [PubMed] [Google Scholar]
  13. Lores B., García-Estevez J. M., Arias C. Lymph nodes and human tumors (review). Int J Mol Med. 1998 Apr;1(4):729–733. doi: 10.3892/ijmm.1.4.729. [DOI] [PubMed] [Google Scholar]
  14. McGrath M. E., Palmer J. T., Brömme D., Somoza J. R. Crystal structure of human cathepsin S. Protein Sci. 1998 Jun;7(6):1294–1302. doi: 10.1002/pro.5560070604. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Morton P. A., Zacheis M. L., Giacoletto K. S., Manning J. A., Schwartz B. D. Delivery of nascent MHC class II-invariant chain complexes to lysosomal compartments and proteolysis of invariant chain by cysteine proteases precedes peptide binding in B-lymphoblastoid cells. J Immunol. 1995 Jan 1;154(1):137–150. [PubMed] [Google Scholar]
  16. Petanceska S., Devi L. Sequence analysis, tissue distribution, and expression of rat cathepsin S. J Biol Chem. 1992 Dec 25;267(36):26038–26043. [PubMed] [Google Scholar]
  17. Pierre P., Mellman I. Developmental regulation of invariant chain proteolysis controls MHC class II trafficking in mouse dendritic cells. Cell. 1998 Jun 26;93(7):1135–1145. doi: 10.1016/s0092-8674(00)81458-0. [DOI] [PubMed] [Google Scholar]
  18. Schweiger A., Stabuc B., Popovíc T., Turk V., Kos J. Enzyme-linked immunosorbent assay for the detection of total cathepsin H in human tissue cytosols and sera. J Immunol Methods. 1997 Feb 28;201(2):165–172. doi: 10.1016/s0022-1759(96)00218-9. [DOI] [PubMed] [Google Scholar]
  19. Seliger B., Maeurer M. J., Ferrone S. Antigen-processing machinery breakdown and tumor growth. Immunol Today. 2000 Sep;21(9):455–464. doi: 10.1016/s0167-5699(00)01692-3. [DOI] [PubMed] [Google Scholar]
  20. Shi G. P., Webb A. C., Foster K. E., Knoll J. H., Lemere C. A., Munger J. S., Chapman H. A. Human cathepsin S: chromosomal localization, gene structure, and tissue distribution. J Biol Chem. 1994 Apr 15;269(15):11530–11536. [PubMed] [Google Scholar]
  21. Sukhova G. K., Shi G. P., Simon D. I., Chapman H. A., Libby P. Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest. 1998 Aug 1;102(3):576–583. doi: 10.1172/JCI181. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Turnsek T., Kregar I., Lebez D. Acid sulphydryl protease from calf lymph nodes. Biochim Biophys Acta. 1975 Oct 22;403(2):514–520. doi: 10.1016/0005-2744(75)90079-0. [DOI] [PubMed] [Google Scholar]
  23. Werle B., Ebert W., Klein W., Spiess E. Assessment of cathepsin L activity by use of the inhibitor CA-074 compared to cathepsin B activity in human lung tumor tissue. Biol Chem Hoppe Seyler. 1995 Mar;376(3):157–164. doi: 10.1515/bchm3.1995.376.3.157. [DOI] [PubMed] [Google Scholar]
  24. Werle B., Kraft C., Lah T. T., Kos J., Schanzenbächer U., Kayser K., Ebert W., Spiess E. Cathepsin B in infiltrated lymph nodes is of prognostic significance for patients with nonsmall cell lung carcinoma. Cancer. 2000 Dec 1;89(11):2282–2291. [PubMed] [Google Scholar]
  25. Werle B., Staib A., Jülke B., Ebert W., Zladoidsky P., Sekirnik A., Kos J., Spiess E. Fluorometric microassays for the determination of cathepsin L and cathepsin S activities in tissue extracts. Biol Chem. 1999 Sep;380(9):1109–1116. doi: 10.1515/BC.1999.138. [DOI] [PubMed] [Google Scholar]
  26. Wiederanders B., Broemme D., Kirschke H., Kalkkinen N., Rinne A., Paquette T., Toothman P. Primary structure of bovine cathepsin S. Comparison to cathepsins L, H, B and papain. FEBS Lett. 1991 Jul 29;286(1-2):189–192. doi: 10.1016/0014-5793(91)80971-5. [DOI] [PubMed] [Google Scholar]
  27. Zavasnik-Bergant V., Sekirnik A., Golouh R., Turk V., Kos J. Immunochemical localisation of cathepsin S, cathepsin L and MHC class II-associated p41 isoform of invariant chain in human lymph node tissue. Biol Chem. 2001 May;382(5):799–804. doi: 10.1515/BC.2001.096. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES